Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited (SPARC) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
sparc.life(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21 Cr | 14 Cr | 17 Cr | 17 Cr | 13 Cr | 15 Cr | 27 Cr | 10 Cr | 8 Cr | 8 Cr | 1,853 Cr | 40 Cr |
| Operating expenses (approx.) | 113 Cr | 116 Cr | 122 Cr | 110 Cr | 116 Cr | 89 Cr | 80 Cr | 62 Cr | 74 Cr | 65 Cr | 80 Cr | 74 Cr |
| EBITDA | -91 Cr | -103 Cr | -106 Cr | -93 Cr | -103 Cr | -74 Cr | -53 Cr | -52 Cr | -66 Cr | -57 Cr | 1,773 Cr | -34 Cr |
| OPM % | -431.9% | -740.4% | -639.1% | -555.4% | -800.2% | -494.2% | -195.6% | -540.2% | -836.1% | -670.3% | 95.7% | -85.2% |
| Other income | 8 Cr | 6 Cr | 4 Cr | 2 Cr | 0.04 Cr | 0.19 Cr | 0 Cr | 9 Cr | 0.01 Cr | 0 Cr | 2 Cr | 24 Cr |
| Interest | 0.26 Cr | 0.26 Cr | 0.91 Cr | 0.56 Cr | 1 Cr | 3 Cr | 5 Cr | 6 Cr | 8 Cr | 9 Cr | 12 Cr | 8 Cr |
| Depreciation | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 2 Cr | 2 Cr |
| Profit before tax | -86 Cr | -100 Cr | -105 Cr | -95 Cr | -107 Cr | -79 Cr | -61 Cr | -52 Cr | -76 Cr | -80 Cr | 1,761 Cr | -21 Cr |
| Tax % | 0.0% | 0.0% | -0.4% | -0.4% | -0.1% | -0.1% | 1.5% | -0.1% | -0.1% | -0.1% | -0.0% | -0.5% |
| Net profit | -86 Cr | -100 Cr | -106 Cr | -96 Cr | -107 Cr | -80 Cr | -60 Cr | -52 Cr | -76 Cr | -80 Cr | 1,761 Cr | -21 Cr |
| EPS (₹) | ₹-2.66 | ₹-3.07 | ₹-3.26 | ₹-2.96 | ₹-3.31 | ₹-2.45 | ₹-1.84 | ₹-1.60 | ₹-2.34 | ₹-2.48 | ₹54.27 | ₹-0.64 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 76 Cr | 72 Cr | 1,879 Cr | Sign in for TTM |
| Operating expenses (approx.) | 478 Cr | 395 Cr | 280 Cr | Sign in for TTM |
| EBITDA | -402 Cr | -323 Cr | 1,599 Cr | Sign in for TTM |
| OPM % | -532.2% | -450.2% | 85.1% | Sign in for TTM |
| Other income | 29 Cr | 2 Cr | 11 Cr | Sign in for TTM |
| Interest | 2 Cr | 9 Cr | 34 Cr | Sign in for TTM |
| Depreciation | 13 Cr | 12 Cr | 10 Cr | Sign in for TTM |
| Profit before tax | -387 Cr | -343 Cr | 1,553 Cr | Sign in for TTM |
| Tax % | -0.1% | 0.1% | -0.0% | Sign in for TTM |
| Net profit | -387 Cr | -343 Cr | 1,553 Cr | Sign in for TTM |
| EPS (₹) | ₹-11.93 | ₹-10.55 | ₹47.86 | Sign in for TTM |
| Dividend payout % | — | — | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 32 Cr | 32 Cr | 32 Cr |
| Reserves | 93 Cr | -249 Cr | 1,306 Cr |
| Borrowings | 47 Cr | 258 Cr | 556 Cr |
| Other liabilities | 342 Cr | 294 Cr | 276 Cr |
| Total liabilities | 515 Cr | 336 Cr | 2,171 Cr |
| Fixed assets (net) | 107 Cr | 99 Cr | 85 Cr |
| CWIP | 1 Cr | 0.56 Cr | 0.50 Cr |
| Investments | 2 Cr | 0 Cr | 0 Cr |
| Loans & advances | 0.22 Cr | 0.16 Cr | 0.17 Cr |
| Trade receivables | 16 Cr | 16 Cr | 8 Cr |
| Cash & bank | 5 Cr | 2 Cr | 1 Cr |
| Other assets | 384 Cr | 218 Cr | 2,076 Cr |
| Total assets | 515 Cr | 336 Cr | 2,171 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | -429 Cr | -360 Cr | -239 Cr |
| Cash from investing | 392 Cr | 158 Cr | -23 Cr |
| Cash from financing | 42 Cr | 199 Cr | 261 Cr |
| Net cash flow | 5 Cr | -3 Cr | -0.80 Cr |
| Free cash flow (OCF − Capex) | -456 Cr | -371 Cr | -263 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | -222.9% | -813.6% | 83.8% |
| ROE % | -307.9% | — | 116.2% |
| Debtor days | 75 | 81 | 2 |
| Inventory days | 0 | 0 | 0 |
| Days payable | 1846 | 1794 | 1498 |
| Cash conversion cycle | -1771 | -1712 | -1497 |
| Debt / equity | 0.37 | 0.00 | 0.42 |
| Current ratio | 1.02 | 0.07 | 2.47 |
| Net debt / EBITDA | — | — | 0.35 |
Compare with peers
Loading peers…